Y-Biologics Inc
338840
Company Profile
Business description
Y-Biologics Inc is a company that has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of the development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.
Contact
B715 Daedeok Biz Center
17 Techno 4-ro, Yuseong-gu
Daejeon34013
KORT: +82 428679971
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
46
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks
Moated AI-proof tech play hiding in the ASX 100
ChatGPT and large language models should be a tailwind for this company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,973.80 | 51.60 | -0.57% |
| CAC 40 | 8,227.32 | 70.89 | 0.87% |
| DAX 40 | 24,155.45 | 39.45 | -0.16% |
| Dow JONES (US) | 49,310.32 | 179.71 | -0.36% |
| FTSE 100 | 10,457.01 | 19.45 | -0.19% |
| HKSE | 25,769.86 | 145.34 | -0.56% |
| NASDAQ | 24,438.50 | 219.06 | -0.89% |
| Nikkei 225 | 59,343.40 | 203.17 | 0.34% |
| NZX 50 Index | 12,886.42 | 1.49 | 0.01% |
| S&P 500 | 7,108.40 | 29.50 | -0.41% |
| S&P/ASX 200 | 8,750.60 | 48.00 | -0.55% |
| SSE Composite Index | 4,074.99 | 18.26 | -0.45% |